A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Creator

Fischer II, William A.
- Affiliation: School of Medicine, Institute for Global Health and Infectious Disease
Eron Jr, Joseph J.
- Affiliation: School of Medicine, Department of Medicine
Holman, Wayne
- Other Affiliation: Ridgeback Biotherapeutics LP
Cohen, Myron S.
- Affiliation: School of Medicine, Institute for Global Health and Infectious Disease
Fang, Lei
- Other Affiliation: Pharstat Inc
Szewczyk, Laura J.
- Other Affiliation: Ridgeback Biotherapeutics LP
Sheahan, Timothy P.
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
Baric, Ralph
- Affiliation: Gillings School of Global Public Health, Department of Epidemiology
Mollan, Katie R.
- Affiliation: School of Medicine
Wolfe, Cameron R.
- Other Affiliation: Duke University Medical Center
Duke, Elizabeth R.
- Other Affiliation: University of Washington
Azizad, Masoud M.
- Other Affiliation: Valley Clinical Trials, Inc.
Borroto-Esoda, Katyna
- Other Affiliation: KBE Consulting
Wohl, David A.
- Affiliation: School of Medicine, Institute for Global Health and Infectious Disease
Coombs, Robert W.
- Other Affiliation: University of Washington
Loftis, Amy James
- Affiliation: School of Medicine, Institute for Global Health and Infectious Disease
Alabanza, Paul
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
Lipansky, Felicia
- Other Affiliation: Ridgeback Biotherapeutics LP
Painter, Wendy P.
- Other Affiliation: Ridgeback Biotherapeutics LP

Abstract

Molnupiravir (800 mg dose) accelerated SARS-CoV-2 RNA clearance in patients with COVID-19 compared to placebo.

Date of publication

DOI

Identifier

Resource type

Rights statement

License

Journal title

Language

Version

Relations